Remitch OD (nalfurafine hydrochloride orally disintegrating tablet) / Toray, Japan Tobacco, Sumitomo Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Remitch OD (nalfurafine hydrochloride orally disintegrating tablet) / Toray, Japan Tobacco, Sumitomo Pharma
NCT04728984: A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

Recruiting
3
135
RoW
Nalfurafine Hydrochloride, Nalfurafine Hydrochloride+Placebo, Placebo
Shenyang Sunshine Pharmaceutical Co., LTD.
Uremic Pruritus
06/21
10/21
ChiCTR2000033326: A single-center phase I clinical study evaluating the pharmacokinetics and safety of single and multiple oral administration of narfurine hydrochloride Orally disintegrating tablets in Chinese healthy adult subjects

Recruiting
1
30
 
Nalfurafine Orally disintegrating tablets provided by Shenyang Sunshine Pharmaceutical Co., Ltd.
The First Affiliated Hospital, Zhejiang University School of Medicine; Shenyang Sunshine Pharmaceutical Co., Ltd., Shenyang Sunshine Pharmaceutical Co., Ltd.
Improvement of pruritus in hemodialysis patients
 
 
ChiCTR2400087915: Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Refractory Pruritus in Patients with Non-Dialysis CKD Stages 3-5

Not yet recruiting
N/A
95
 
Nalfurafine Hydrochloride Orally Disintegrating Tablets 2.5 μg, once daily, for 14 consecutive days
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Shenyang Sansheng Pharmaceutical Co., LTD
chronic kidney disease associated Pruritus
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Remitch OD (nalfurafine hydrochloride orally disintegrating tablet) / Toray, Japan Tobacco, Sumitomo Pharma
NCT04728984: A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

Recruiting
3
135
RoW
Nalfurafine Hydrochloride, Nalfurafine Hydrochloride+Placebo, Placebo
Shenyang Sunshine Pharmaceutical Co., LTD.
Uremic Pruritus
06/21
10/21
ChiCTR2000033326: A single-center phase I clinical study evaluating the pharmacokinetics and safety of single and multiple oral administration of narfurine hydrochloride Orally disintegrating tablets in Chinese healthy adult subjects

Recruiting
1
30
 
Nalfurafine Orally disintegrating tablets provided by Shenyang Sunshine Pharmaceutical Co., Ltd.
The First Affiliated Hospital, Zhejiang University School of Medicine; Shenyang Sunshine Pharmaceutical Co., Ltd., Shenyang Sunshine Pharmaceutical Co., Ltd.
Improvement of pruritus in hemodialysis patients
 
 
ChiCTR2400087915: Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Refractory Pruritus in Patients with Non-Dialysis CKD Stages 3-5

Not yet recruiting
N/A
95
 
Nalfurafine Hydrochloride Orally Disintegrating Tablets 2.5 μg, once daily, for 14 consecutive days
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Shenyang Sansheng Pharmaceutical Co., LTD
chronic kidney disease associated Pruritus
 
 

Download Options